NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
A new study of over 246,000 heart disease patients shows the shingles vaccine reduces major cardiovascular events by 46% and death by 61% within one year. The protective effects are comparable to quitting smoking and support existing vaccine recommendations for adults over 50. The findings will be presented at the American College of Cardiology's annual meeting.
Oral semaglutide demonstrated significant improvements in multiple cardiometabolic risk factors in adults with type 2 diabetes at high cardiovascular risk. The SOUL trial analysis showed reductions in systolic blood pressure, cholesterol, triglycerides, HbA1c, and body weight compared to placebo. These benefits were observed as early as 13 weeks and contributed to a 14% reduction in major adverse cardiovascular events.
Novo Nordisk received FDA approval for a 7.2-mg semaglutide dose marketed as Wegovy HD for adult patients with obesity who have tolerated the standard 2.4-mg dose. The approval came through the FDA's new Commissioner's National Priority Voucher pilot program.
New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.
New real-world effectiveness data presented at RSVVW'26 demonstrate that GSK's Arexvy RSV vaccine was associated with a 75.6% reduction in RSV-related hospitalizations among adults aged 60 and older, with exploratory findings suggesting potential benefits for cardiovascular and respiratory complications.
The cardiovascular biologics market is projected to reach $4.23 billion by 2033, while the cell therapy market is expected to reach $5.38 billion by 2032, driven by RNA-based therapies and regulatory approvals.
New studies show SGLT2 inhibitors and GLP-1 receptor agonists reduce risks of kidney failure, cardiovascular events, and liver complications in patients with type 2 diabetes, with particularly strong benefits in those with cirrhosis.
A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07507110 |
Relationship Between RAR and MACEs in AMI-CS Patients During Hospitalization |
COMPLETED | |
| NCT07089589 |
Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients |
COMPLETED | |
| NCT07057713 |
Total Arterial vs. Mixed Grafting in Left Coronary CABG |
NOT_YET_RECRUITING | NA |
| NCT06885619 |
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis |
RECRUITING | |
| NCT06355219 |
Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines |
COMPLETED | |
| NCT06318767 |
Predictive Value of Systolic Rise Time of the Plantar Arch on the Risk of Major Adverse Limb Events (MALE) and Major Adverse Cardiovascular Events (MACE) in Peripheral Artery Disease (PAD) at Critical Ischaemia Stage |
RECRUITING | NA |
| NCT05623995 |
Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO) |
RECRUITING | PHASE4 |
| NCT04691037 |
CCTA Improves Clinical Management of Stable Chest Pain |
RECRUITING | |
| NCT04580017 |
Prognostic Accuracy of the HEART Score in Undifferentiated Chest Pain: A Multicenter Validation Study |
COMPLETED | |
| NCT03175952 |
Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention. |
UNKNOWN |
